Page 25 - Read Online

carcinoma incidence in patients with hepatitis B virus infection. periodic cancer screening for improving outcomes. J Gastroenterol
Hepatology 2013;58:98-107. 2014;49:1504-13.
43. Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral 60. Moon C, Jung KS, Kim do Y, Baatarkhuu O, Park JY, Kim BK,
hepatitis-related liver fibrosis. Int J Mol Sci 2014;15:10578-604. Kim SU, Ahn SH, Han KH. Lower incidence of hepatocellular
44. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, carcinoma and cirrhosis in hepatitis C patients with sustained
Kanamori A, Niinomi T, Yasuda S, Andou Y, Yamamoto K, Tanaka virological response by pegylated interferon and ribavirin. Dig Dis
J. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis Sci 2015;60:573-81.
in chronic hepatitis B patients: a propensity score analysis. J Hepatol 61. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect
2013;58:427-33. of interferon therapy on the development of hepatocellular carcinoma
45. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico in patients with hepatitis C virus-related cirrhosis: a meta-analysis.
P. Risk of hepatocellular carcinoma in chronic hepatitis B: Aliment Pharmacol Ther 2001;15:689-98.
assessment and modification with current antiviral therapy. J Hepatol 62. Craxì A, Cammà C. Prevention of hepatocellular carcinoma. Clin
2015;62:956-67. Liver Dis 2005;9:329-46.
46. Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY Wu C, Wu JC. 63. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y.
Association of nucleos(t)ide analogue therapy with reduced risk Eradication of hepatitis C virus infection and the development of
of hepatocellular carcinoma in patients with chronic hepatitis B: a hepatocellular carcinoma: a meta-analysis of observational studies.
nationwide cohort study. Gastroenterology 2014;147:143-51. Ann Intern Med 2013;158:329-37.
47. Chan AC, Chok KS, Yuen WK, Chan SC, Poon RT, Lo CM, Fan ST. 64. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De
Impact of antiviral therapy on the survival of patients after major Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL,
hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Morishima C, Lindsay KL, Lok AS; HALT-C Trial Group. Outcome
Arch Surg 2011;146:675-81. of sustained virological responders with histologically advanced
48. Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou chronic hepatitis C. Hepatology 2010;52:833-44.
WP, Wu MC. Antiviral therapy improves postoperative survival in 65. Thévenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T.
patients with hepatocellular carcinoma: a randomized controlled Metaanalysis of interferon randomized trials in the treatment of viral
trial. Ann Surg 2015;261:56-66. hepatitis C in naive patients: 1999 update. J Viral Hepat 2001;8:48-
49. Nordenstedt H, White DL, El-Serag HB. The changing pattern 62.
of epidemiology in hepatocellular carcinoma. Dig Liver Dis 66. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna
2010;42:S206-14. M, Rose N, Verbaan H, Stål P, Carlsson T, Norrgren H, Ekbom A,
50. Goodgame B, Shaheen NJ, El-Serag HB. The risk of end stage liver Granath F, Hultcrantz R. A risk for hepatocellular carcinoma persists
disease and hepatocellular carcinoma among persons infected with long-term after sustained virologic response in patients with hepatitis
hepatitis C virus: publication bias? Am J Gastroenterol 2003;98:2535- C-associated liver cirrhosis. Clin Infect Dis 2013;57:230-6.
42. 67. Pinzoni MR, Zanghì AM, Rapisarda L, D’Agata V, Benanti F,
51. Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Spartà D, Nunnari G, Capopardo B. Cirrhotic patients are still at
Pathogenesis and prevention of hepatitis C virus-induced risk of developing hepatocellular carcinoma despite interferon-
hepatocellular carcinoma. J Hepatol 2014;61:S79-90. induced sustained virological response. Eur Rev Med Pharmacol Sci
52. Bruix J, Sherman M; Practice Guidelines Committee, American 2014;18:11-5.
Association for the Study of Liver Diseases. Management of 68. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M,
hepatocellular carcinoma. Hepatology 2005;42:1208-36. Yasui Y, Hosokawa T, Ueda K, Kuzuya T, Nakanishi H, Itakura J,
53. Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, Hsu Takahashi Y, Kurosaki M, Enomoto N, Izumi N. Effect of aging
HM, Chen HL, Hsu HY, Chen DS; Taiwan Childhood Hepatoma on risk for hepatocellular carcinoma in chronic hepatitis C virus
Study Group. Hepatitis B vaccination and hepatocellular carcinoma infection. Hepatology 2010;52:518-27.
rates in boys and girls. JAMA 2000;284:3040-2. 69. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF,
54. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L,
M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL.
Peginterferon alfa-2b plus ribavirin compared with interferon Association between sustained virological response and all-cause
alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a mortality among patients with chronic hepatitis C and advanced
randomized trial. Lancet 2001;358:958-65. hepatic fibrosis. JAMA 2012;308:2584-93.
55. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales 70. Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta
FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada
A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic H, Kobayashi T. Effect of type 2 diabetes on risk for malignancies
hepatitis C virus infection. N Engl J Med 2002;347:975-82. includes hepatocellular carcinoma in chronic hepatitis C. Hepatology
56. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin 2013;57:964-73.
P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem 71. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart
S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR,
Group. Peginterferon-alpha 2a and ribavirin combination therapy in Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial
chronic hepatitis C: a randomized study of treatment duration and Investigators. Prolonged therapy of advanced chronic hepatitis C
ribavirin dose. Ann Intern Med 2004;140:346-55. with low-dose peginterferon. N Engl J Med 2008;359:2429-41.
57. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima 72. Afdhal NH, Levine R, Brown RS, Freilich B, OíBrien M, Brass C.
S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomised trial of Colchichine versus peg-interferon alfa-2b long term therapy: results
effects of interferon-alpha on incidence of hepatocellular carcinoma of the 4 year copilot trial. J Hepatol 2008;48:S4.
in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5. 73. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-
58. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ,
Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma GonÁales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay
in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol P, Griffel L, Burroughs M, Brass C, Albrecht J; Epic Study Group.
Hepatol 2010;8:192-9. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis
59. Yamashita N, Ohho A, Yamasaki A, Kurokawa M, Kotoh K, Kajiwara C who failed interferon alfa/ribavirin therapy. Gastroenterology
E. Hepatocarcinogenesis in chronic hepatitis C patients achieving a 2009;136:1618-28.e2.
sustained virological response to interferon: significance of lifelong 74. Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto

16 Hepatoma Research | Volume 2 | Issue 1 | January 15, 2016